Evidence-based somatic treatment of depression in adults

Psychiatric Clinics of North America

Volumn 35, Issue 1, 2012, Pages 131-142

  Carlat, Daniel ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Efficacy studies; Selective serotonin reuptake inhibitors; Serotonin norepinephrine reuptake inhibitors; STAR D trial

Indexed keywords

AMFEBUTAMONE; ATROPINE; BUSPIRONE; CHLORPROMAZINE; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PRISTIG; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VENLAFAXINE; VILAZODONE;

BULIMIA; CLINICAL EFFECTIVENESS; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PANIC; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHIATRIST; REVIEW; SEASONAL AFFECTIVE DISORDER; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CLINICAL TRIALS AS TOPIC; DEPRESSION; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED PRACTICE; HUMANS; META-ANALYSIS AS TOPIC; NEUROTRANSMITTER UPTAKE INHIBITORS; PLACEBOS; TREATMENT OUTCOME;

EID: 84857382927     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2011.11.002     Document Type: Review

References (18)

1. Kirsch I. The emperor's new drugs: exploding the antidepressant myth 2010, Basic Books, Philadelphia.
2. Healy D. The antidepressant era 2000, 91. Harvard University Press, Cambridge (MA).
3. Kirsch I., Deacon B.J., Huedo-Medina T.B., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5:e45.
4. Turner E.H., Matthews A.M., Linardatos E., et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358:252-260.
5. Greenberg R.P., Bornstein R.F., Zborowski M.J., et al. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994, 82:547-551.
6. Moncrieff J., Wessely S., Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004, 1. CD003012.
7. Turner E., Rosenthal R. Efficacy of antidepressants. BMJ 2008, 336:516-517.
8. Levkovitz Y., Tedeschini E., Papakostas G. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2011, 72(4):509-514.
9. Zimmerman M., Mattia J.I., Posternak M.A. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am J Psychiatry 2002, 159:469-473.
10. Fournier J.C., DeRubeis R.J., Hollon S.D., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303(1):47-53.
11. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
12. Gaynes B.N., Warden D., Trivedi M.H., et al. What did STAR*D teach us?. Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009, 60:1439-1445.
13. Pigott H.E., Leventhal A.M., Alter G.S., et al. Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 2010, 79:267-279.
14. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001, 178:234-241.
15. Nemeroff C.B., Entsuah R., Benattia I., et al. Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs. Biol Psychiatry 2008, 63(4):424-434.
16. Schueler Y.B., Koesters M., Wieseler B., et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatrica Scand 2011, 23:247-265.
17. Gartlehner G., Gaynes B.N., Hansen R.A. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008, 149:734-750.
18. Cipriani A., Furukawa T.A., Salanti G., et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758.